![Ksenija Aranicki Pavletic](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ksenija Aranicki Pavletic
Directeur/Bestuurslid bij MaxiVAX SA
Oorsprong van het eerstegraads netwerk van Ksenija Aranicki Pavletic
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
MaxiVAX SA
![]() MaxiVAX SA Miscellaneous Commercial ServicesCommercial Services MaxiVAX SA is a Swiss clinical stage biotechnology company. The private company is based in Geneva, Switzerland. The company was founded by Bernard Mach.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Ksenija Aranicki Pavletic via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
The University of Alabama | College/University | Doctorate Degree | |
LONZA GROUP AG | Pharmaceuticals: Major | Director/Board Member | |
Metriopharm AG
![]() Metriopharm AG Pharmaceuticals: MajorHealth Technology Metriopharm AG engages in the development and manufacture of pharmaceutical products. It offers pipeline, indicators and clinical trials. The company was founded by Ekkehard Brysch and Wolfgang Brysch in 2007 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO | |
University of Fribourg | College/University | Undergraduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
NOVIMMUNE SA | Medical/Nursing Services | Founder | |
JSB-Partners LP
![]() JSB-Partners LP Investment Banks/BrokersFinance JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA. | Investment Banks/Brokers | Founder | |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
The Rockefeller University | College/University | Doctorate Degree | |
University of Geneva | College/University | Corporate Officer/Principal | |
Atalanta Therapeutics, Inc.
![]() Atalanta Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor. | Miscellaneous Commercial Services | Director/Board Member | |
Vero Biotech LLC
![]() Vero Biotech LLC Pharmaceuticals: MajorHealth Technology Vero Biotech LLC is a biotechnology company, which focuses on the design, development and commercialization of inhaled nitric oxide delivery systems to address the unmet medical needs of patients with cardiopulmonary conditions. It develops a drug, GeNOsyl to meet the needs of patients and care providers. The company was founded by David H. Fine in 2006 and is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Director/Board Member | |
THE MEDICINES COMPANY | Pharmaceuticals: Major | Founder | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal | |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Chief Executive Officer |
Statistieken
Internationaal
Zwitserland | 11 |
Verenigde Staten | 9 |
Verenigd Koninkrijk | 2 |
Frankrijk | 2 |
Sectoraal
Health Technology | 10 |
Consumer Services | 6 |
Finance | 4 |
Health Services | 2 |
Miscellaneous | 2 |
Operationeel
Director/Board Member | 9 |
Founder | 6 |
Corporate Officer/Principal | 5 |
Doctorate Degree | 4 |
Director of Finance/CFO | 3 |
Sterkste connecties
Insiders | |
---|---|
Sven Zimmermann | 8 |
Bernard Mach | 8 |
T. Scott Johnson | 7 |
Clarence Peter | 1 |
- Beurs
- Insiders
- Ksenija Aranicki Pavletic
- Bedrijfsconnecties